Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Phio Pharmaceuticals Corp. (PHIO)

Phio Pharmaceuticals Q3 net loss widens to $4.2 million on PH-762 spending

Negative Impact 3 of 5 earnings Written later

Phio Pharmaceuticals reported a third-quarter 2026 net loss of $4.2 million, up from $2.4 million a year earlier, as research and development costs for its PH-762 program rose sharply. Cash and cash equivalents fell to $10.6 million at September 30, 2026, from $21.0 million at December 31, 2025, and the company's stockholders' equity declined to $8.6 million, so shareholders face a larger loss and a smaller cash balance.

Key points

  • Q3 2026 research and development expenses were $3.0 million, up $1.9 million or 159% from the prior-year quarter, driven mainly by nonclinical toxicology, drug substance and clinical supply costs.
  • Nine-month 2026 net loss was $12.3 million, compared with $6.3 million in the same period of 2025.
  • Cash and cash equivalents were $10.6 million at September 30, 2026, versus $21.0 million at December 31, 2025.
  • The company expects FDA feedback on its submission by the end of November 2026 and plans to start the Phase 2b study of PH-762 in the first quarter of 2027.

The filing

CompanyPhio Pharmaceuticals Corp. (PHIO)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:12 PM ET
Accession number0001437749-26-035277

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.